A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Nov 2017
At a glance
- Drugs HIV vaccine-vCP2438 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2017 Planned End Date changed from 5 Dec 2018 to 30 Sep 2019.
- 08 Nov 2017 Planned primary completion date changed from 5 Dec 2018 to 30 Sep 2019.
- 08 Nov 2017 Planned initiation date changed from 5 Jun 2017 to 18 Dec 2017.